José Mário Mariz

José Mário Mariz

Auto-generated profile, based on publicly available information

José Mário Mariz

Instituto Portugues de Oncologia do Porto Francisco Gentil Porto Portugal

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
JMJuan Eduardo Megías-Vericat
Juan Eduardo Megías-Vericat
JSJosefina Serrano
Josefina Serrano
PMPilar Martínez-Sánchez
Pilar Martínez-Sánchez
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
PMPau Montesinos
Pau Montesinos
Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group ≥2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P < .001). Median OS was higher for de novo than sAML (10.9 vs 5.6 months; P < .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P = .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after hypomethylating agents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value. This trial was registered at www.clinicaltrials.gov as #NCT02607059.

21 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MSMarta Sobas
Marta Sobas
MTMaria Carme Talarn-Forcadell
Maria Carme Talarn-Forcadell
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
LELourdes Escoda
Lourdes Escoda
MPMARIA JOSE GARCIA PEREZ
MARIA JOSE GARCIA PEREZ
PMPau Montesinos
Pau Montesinos
It has been suggested that 1–2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RARα being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RARα and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Of 2895 patients with genetically confirmed APL in the PETHEMA registry, 11 had variant APL (0.4%) (9 PLZF-RARα and 2 NPM1-RARα), 9 were men, with median age of 44.6 years (3 months to 76 years), median leucocytes (WBC) 16.8 × 109/L, and frequent coagulopathy. Eight patients were treated with ATRA plus chemotherapy-based regimens, and 3 with chemotherapy-based. As compared to previous reports, complete remission and survival was slightly better in our cohort, with 73% complete remission (CR) and 73% survival despite a high relapse rate (43%). After analyzing our series and performing a comprehensive and critical review of the literature, strong recommendations on appropriate management of variant APL are not possible due to the low number and heterogeneity of patients reported so far.

12 December 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NCNuno Cerveira
Nuno Cerveira
BLBruno Loureiro
Bruno Loureiro
SBSusana Bizarro
Susana Bizarro
CCCecília Correia
Cecília Correia
MTMaria de Lurdes Torres
Maria de Lurdes Torres
JMJosé M. Mariz
José M. Mariz
Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can stop therapy without relapsing. However, most information on treatment cessation was obtained from clinical trials with strict recruiting criteria. We evaluated the outcome of 25 patients with CML that discontinued TKI therapy in our institute in real-world clinical practice. Of the 25 patients, 76% discontinued therapy in sustained deep molecular response (SDMR) and 24% were in unsustained DMR (UDMR). Discontinuation of therapy due to adverse effects was observed in 5 and 50% of the patients in the SDMR and UDMR groups, respectively. After TKI discontinuation, patients were followed for a median of 24 months. At the time of this analysis, 56% patients had a molecular relapse after a median of 4 months. SDMR and longer treatment duration were associated with lower probability of molecular relapse: 25% in SDMR patients with TKI treatment > 96 months and 85% in UDMR patients with TKI treatment ≤96 months. All relapsed patients promptly resumed TKI therapy and regained at least major molecular response (MMR). Our results suggest that TKI discontinuation is safe outside clinical trials and particularly effective in CML patients who are in SDMR with longer TKI treatment duration.

18 January 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SLSusana Lisboa
Susana Lisboa
NCNuno Cerveira
Nuno Cerveira
SBSusana Bizarro
Susana Bizarro
CCCecília Correia
Cecília Correia
JVJoana Vieira
Joana Vieira
MTManuel R. Teixeira
Manuel R. Teixeira
Background: NUP98 gene rearrangements have been reported in acute myeloid leukemia, giving rise to fusion proteins that seem to function as aberrant transcription factors, and are thought to be associated with poor prognosis. Findings: A patient with treatment-related acute myeloid leukemia presented a t(3;11)(p11;p15) as the only cytogenetic abnormality. FISH and molecular genetic analyses identified a class 1 homeobox gene, POU1F1, located on chromosome 3p11, as the fusion partner of NUP98. In addition, we have found that the patient harbored an FLT3-ITD mutation, which most likely collaborated with the NUP98-POU1F1 fusion gene in malignant transformation. Conclusions: We have identified POU1F1 as the NUP98 fusion partner in therapy-related AML with a t(3;11)(p11;p15). This is the first POU family member identified as a fusion partner in human cancer.

1 February 2012 in Current Opinion in Oncology
Verified
Journal Article
Closed access
JMJosé Mário Mariz
José Mário Mariz
GEGraça Vasconcelos Esteves
Graça Vasconcelos Esteves
Multiple myeloma is a malignant neoplasm of plasma cells, for which there is no known cure. This article examines the efficacy and tolerability of lenalidomide, a potent structural analogue of thalidomide, for the treatment of patients with relapsed/refractory multiple myeloma. Lenalidomide, a thalidomide analogue, was designed to provide increased efficacy, while avoiding the adverse effects associated with thalidomide therapy. Studies assessing lenalidomide as therapy for relapsed/refractory multiple myeloma have shown promising beneficial effects. Lenalidomide–dexamethasone is associated with significantly longer median time to disease progression and overall survival, as well as a significantly higher proportion of patients who respond to treatment compared with dexamethasone alone. Lenalidomide (with dexamethasone) was associated with a high rate of myelosuppression in clinical trials; neutropenia, infection, thrombocytopenia, and venous thromboembolism were common grade 3–4 adverse events. However, appropriate management of these adverse events maximizes the clinical benefit of lenalidomide. Lenalidomide in combination with dexamethasone is approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of patients with relapsed/refractory multiple myeloma. Lenalidomide is recommended as a treatment option for patients with multiple myeloma in both United States and European treatment guidelines.

17 August 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
MLMarta Lopes
Marta Lopes
TDTiago L Duarte
Tiago L Duarte
MTMaria Jose Teles
Maria Jose Teles
LMLaura Mosteo
Laura Mosteo
SCSergio Chacim
Sergio Chacim
DDDelfim Duarte
Delfim Duarte
Acute myeloid leukemia (AML) is a heterogeneous disease with poor prognosis and limited treatment strategies. Determining the role of cell-extrinsic regulators of leukemic cells is vital to gain clinical insights into the biology of AML. Iron is a key extrinsic regulator of cancer, but its systemic regulation remains poorly explored in AML. To address this question, we studied iron metabolism in patients with AML at diagnosis and explored the mechanisms involved using the syngeneic MLL-AF9–induced AML mouse model. We found that AML is a disorder with a unique iron profile, not associated with inflammation or transfusion, characterized by high ferritin, low transferrin, high transferrin saturation (TSAT), and high hepcidin. The increased TSAT in particular, contrasts with observations in other cancer types and in anemia of inflammation. Using the MLL-AF9 mouse model of AML, we demonstrated that the AML-induced loss of erythroblasts is responsible for iron redistribution and increased TSAT. We also show that AML progression is delayed in mouse models of systemic iron overload and that elevated TSAT at diagnosis is independently associated with increased overall survival in AML. We suggest that TSAT may be a relevant prognostic marker in AML.